Benchmark Raises Price Targets: INBK +6% to $35, DXCM +6.5% to $82

On July 31, 2026, equity research firm Benchmark simultaneously raised price targets on two distinctly different companies: First Internet Bancorp (NASDAQ: INBK) and DexCom (NASDAQ: DXCM), signaling sector-specific conviction amid a mixed market environment. The INBK target was lifted from $33 to $35, representing a 21.74% upside from the stock’s opening price of $28.75 that day, while the DXCM target moved from $77 to $82, implying a slight 0.63% downside from its $82.52 opening price. Both stocks retained “buy” ratings, indicating Benchmark sees intrinsic value beyond near-term price fluctuations. These revisions arrive at a time when small-cap banks and med-tech giants face divergent macroeconomic pressures — rising interest rates weigh on bank margins while healthcare innovation continues to attract defensive capital. Benchmark’s simultaneous upgrades suggest a selective optimism: for INBK, the firm may be pricing in improved net interest margins or credit quality recovery, whereas for DXCM, the increase likely reflects confidence in continuous glucose monitoring market expansion despite a stretched valuation. The contrasting market positions are stark: INBK carries a negative P/E of -6.90, a micro-cap status with a $250.61 million market cap, and a debt-to-equity of 0.96, while DXCM boasts a $31.84 billion market cap, a P/E of 34.96, and healthy liquidity ratios. Benchmark’s $35 target for INBK aligns with the higher end of the current analyst consensus range (average $28.50, with a hold rating), potentially acting as a catalyst for re-rating if earnings stabilize. For DXCM, the consensus target is already $85.58, with 21 buy-equivalent ratings out of 27, indicating Benchmark’s new target is near the upper tier but the slight downside reflects limited near-term upside. The broader analyst community has been increasingly constructive on both names: INBK saw Piper Sandler lift its target to $26 in late June, Wall Street Zen upgraded to buy, and Keefe, Bruyette & Woods edged up to $24; DXCM received upward revisions from TD Cowen ($95) and Mizuho ($90), among others. The net effect is a diverging risk profile — investors in INBK are betting on a turnaround story with high upside potential, while DXCM holders must weigh the premium valuation against consistent growth. From a market impact standpoint, such high-visibility upgrades from Benchmark, disseminated via Benzinga, often generate immediate trading volume spikes and can reinforce bullish sentiment in small-cap financials. Looking ahead, INBK’s next earnings report will be pivotal to validate expectations embedded in the new price target, while DXCM’s path hinges on maintaining its innovation lead and fending off competition in the glucose monitoring space. Overall, the July 31 upgrades underscore Benchmark’s thesis that niche value exists across the market spectrum, and they provide a clear data point for portfolio construction balancing risk and reward.